NCT01380184 2019-04-19
MK-8669-059
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
4 trialsNCT00086125 2015-08-19
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01071304 2015-04-10
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00112372 2015-02-12
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed